A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia

Summary

The main purpose of this study is to evaluate the efficacy and safety of the study drug known as evacetrapib in Japanese participants with primary hypercholesterolemia. The double blind treatment period will last for 12 weeks and the open-label extension period will last for an additional 40 weeks.

Timeline

Start

2014-11

Primary completion

2015-07

Completion

2015-12

Outcome

Outcome not reported

Stopped: “Study termination due to insufficient efficacy.”

Drugs

Indications